Regulatory Harmonization Progress: MDSAP, IMDRF, and the Path to Mutual Recognition
Cross-border regulatory alignment is accelerating. We assess MDSAP audit data, IMDRF convergence initiatives, and what the latest bilateral agreements mean for global market access timelines.
The Medical Device Single Audit Program has now completed its seventh full year as an operational framework, with participating regulatory members — FDA, Health Canada, ANVISA, TGA, and PMDA — sharing audit results across approximately 4,200 manufacturer sites as of the latest published program data. MDSAP's maturation has been gradual but measurable: audit cycle times have compressed as auditing organizations have developed deeper expertise with the MDSAP audit model, and the rate of serious findings requiring immediate agency notification has declined year-over-year as manufacturers have internalized the program's quality management system expectations.
The IMDRF's work program in 2025–2026 has advanced on several fronts relevant to global market access. The Software as a Medical Device (SaMD) framework, originally published in 2013, has received substantive updates reflecting the AI/ML context, with a new IMDRF document on predetermined change protocols — closely aligned with FDA's PCCP guidance — approved for final publication in Q1 2026. The In Vitro Diagnostic working group has finalized a harmonized essential principles checklist that is now referenced in regulatory submissions to at least eleven IMDRF member jurisdictions. These outputs matter less as legally binding instruments and more as coordination mechanisms that reduce the cross-jurisdictional divergence that forces manufacturers to maintain parallel technical documentation.
The most commercially significant harmonization development of the past twelve months is the operationalization of the US–UK Mutual Recognition Agreement for conformity assessment of medical devices. While the MRA stops short of full reliance — FDA and MHRA retain independent review authority — it creates an expedited pathway for devices with existing FDA clearance to achieve UK CA marking through a streamlined technical review that acknowledges the FDA submission data rather than requiring full parallel documentation. Our signal data captures the first cohort of devices completing this pathway, with review timelines averaging 4.2 months compared to the 11.8-month average for standard UKCA submissions in the pre-MRA period.
The trajectory of regulatory harmonization is positive but uneven. Bilateral agreements and IMDRF convergence documents are reducing friction at the margins of multi-market submissions, but the fundamental divergence between major frameworks — particularly between FDA's risk-benefit paradigm and the EU MDR's clinical evidence architecture — remains substantial enough that global submissions continue to require jurisdiction-specific customization. Manufacturers that invest in modular technical documentation designed around IMDRF common submission templates are best positioned to leverage harmonization gains as they accrue, without needing to rebuild documentation strategies each time a new bilateral agreement takes effect.